A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid

NCT01707069 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergic Rhinoconjunctivitis

Interventions

BIOLOGICAL: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection

Sponsor

Immunomic Therapeutics, Inc.